Stakeholders ask FDA to be more flexible on rescinding breakthrough drugs designations

Pharmaceutical stakeholders want the US Food and Drug Administration to be more flexible when revoking breakthrough therapy designations (BTD). In comments on a recent draft guidance, they made several suggestions including allowing breakthrough drugs to stay on the market in certain cases even if an alternative treatment becomes available.